Black Diamond Therapeutics, Inc. Common Stock BDTX
i
Market datapartial · fetched 2026-11-07T07:42:26.351Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:00.372810353Z
FundamentalsAlpha Vantage · unavailable
Black Diamond Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.27 | 645.5% | 55.7% | |||
| 25Δ | 1.46 | 535.7% | 44.8% | |||
| 30Δ | 1.58 | 472.3% | 38.0% | |||
| 35Δ | 1.67 | 421.8% | 32.5% | |||
| 40Δ | 1.77 | 371.3% | 26.9% | |||
| 45Δ | 6.39 | 710.6% | 292.4% | 1.86 | 320.8% | 21.4% |
| 50Δ | 4.89 | 614.0% | 206.8% | 1.96 | 270.3% | 15.8% |
| 55Δ | 3.38 | 517.3% | 121.3% | |||
| 60Δ | 1.98 | 423.1% | 41.6% | |||
| 65Δ | 1.76 | 355.8% | 28.5% | |||
| 70Δ | 1.53 | 288.6% | 15.5% | |||
| 75Δ | 1.41 | 264.1% | 11.6% | |||
| 80Δ | 1.31 | 245.8% | 9.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.27
- IV
- 645.5%
- B/E move
- 55.7%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.46
- IV
- 535.7%
- B/E move
- 44.8%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.58
- IV
- 472.3%
- B/E move
- 38.0%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.67
- IV
- 421.8%
- B/E move
- 32.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.77
- IV
- 371.3%
- B/E move
- 26.9%
45Δ
- Pseudo strike
- 6.39
- IV
- 710.6%
- B/E move
- 292.4%
- Pseudo strike
- 1.86
- IV
- 320.8%
- B/E move
- 21.4%
50Δ
- Pseudo strike
- 4.89
- IV
- 614.0%
- B/E move
- 206.8%
- Pseudo strike
- 1.96
- IV
- 270.3%
- B/E move
- 15.8%
55Δ
- Pseudo strike
- 3.38
- IV
- 517.3%
- B/E move
- 121.3%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 1.98
- IV
- 423.1%
- B/E move
- 41.6%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 1.76
- IV
- 355.8%
- B/E move
- 28.5%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 1.53
- IV
- 288.6%
- B/E move
- 15.5%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 1.41
- IV
- 264.1%
- B/E move
- 11.6%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 1.31
- IV
- 245.8%
- B/E move
- 9.0%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 141.58% | |
| 150.20% | |
| 148.48% | |
| 104.87% | |
| 129.39% | |
| 161.28% | |
| 120.49% | |
| 113.26% | |
| 123.60% | |
| 124.37% | |
| 128.02% | |
| 135.86% | |
| 157.59% | |
| 198.56% | |
| 213.47% | |
| 164.58% | |
| 164.24% | |
| 204.79% | |
| 239.71% | |
| 201.68% | |
| 161.00% | |
| 175.16% | |
| 125.94% | |
| 177.44% | |
| 161.42% | |
| 185.52% | |
| 191.08% | |
| 165.58% | |
| 197.41% | |
| 248.43% | |
| 234.77% | |
| 291.06% | |
| 271.26% | |
| 173.94% | |
| 160.77% | |
| 175.91% | |
| 166.79% | |
| 162.10% | |
| 191.08% | |
| 190.14% | |
| 203.12% | |
| 186.45% | |
| 169.56% | |
| 195.03% |
Biotechnology
BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in…
More →BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The…
More →BLTE
Description unavailable
More →BMEA
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically…
More →BMRN
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San…
More →BNTC
Benitec Biopharma Inc., a developing biotechnology company, is focused on the development of new genetic drugs. The company is headquartered in Hayward, California.
More →